
Commentary|Podcasts|September 5, 2025
Sifting Through Discordant Data From ESC 2025
Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.
Advertisement
Following the European Society of Cardiology Congress 2025, experts sat down again with host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-cards), CACP, to discuss key findings from the meeting. Kaitlin Hile, PharmD, BCCP; Robert Page, PharmD, MSPH, BCPS (AQ-cards), BCGP, FAHA, FHFSA, FCCP, FASHP; and Robert DiDomenico, PharmD, FCCP, FHFSA, FACC, reviewed new data from the meeting and parsed through their lingering questions.
For more information:
Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction (REBOOT; NCT03596385)Beta-Blockers After Myocardial Infarction in Patients Without Heart Failure (BETAMI–DANBLOCK; NCT03646357, NCT03778554)Digitoxin in Patients With Heart Failure and Reduced Ejection Fraction (DIGIT-HF)Vericiguat in Patients With Chronic Heart Failure and Reduced Ejection Fraction (VICTOR): A Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial (NCT05093933)
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
3
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
4
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
5





































































































